Circulating tumour DNA assays in focus: highlights from ASCO 2025 for clinicians

Q: What type of study is this?

This is a Literature Review study.

Maria Coakley; Javier Pascual; Séamus O’Reilly

doi:10.1038/s44276-025-00181-y

September 19, 2025BJC ReportsOpen Access

Circulating tumour DNA assays in focus: highlights from ASCO 2025 for clinicians

View Full Paper

Ask AI

Bookmark

Share

Key Points

ctDNA assays enhance detection methods in both early and advanced disease stages, improving diagnostic accuracy.
Importance of ctDNA assays is underscored by ongoing challenges in screening methods and their clinical applications.
Advancements from ASCO 2025 reveal potential for ctDNA in overcoming detection barriers in cancer diagnosis.
Clinical settings are still grappling with limitations in ctDNA assay standardization and implementation.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Review highlights challenges and advancements in ctDNA assays for early and advanced disease detection.

Abstract

Summary of key clinical research settings and remaining challenges for ctDNA assays post ASCO Annual meeting 2025 including detection and screening, early disease and advanced disease settings.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Coakley et al. (2025) studied this question.

synapsesocial.com/papers/68d46cbf31b076d99fa68a26 https://doi.org/10.1038/s44276-025-00181-y

View Full Paper

Ask AI

Bookmark

Share

Circulating tumour DNA assays in focus: highlights from ASCO 2025 for clinicians

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Circulating tumour DNA assays in focus: highlights from ASCO 2025 for clinicians

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading